JP2017527561A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527561A5
JP2017527561A5 JP2017512320A JP2017512320A JP2017527561A5 JP 2017527561 A5 JP2017527561 A5 JP 2017527561A5 JP 2017512320 A JP2017512320 A JP 2017512320A JP 2017512320 A JP2017512320 A JP 2017512320A JP 2017527561 A5 JP2017527561 A5 JP 2017527561A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
formula
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017512320A
Other languages
English (en)
Japanese (ja)
Other versions
JP6692350B2 (ja
JP2017527561A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/048429 external-priority patent/WO2016037005A1/en
Publication of JP2017527561A publication Critical patent/JP2017527561A/ja
Publication of JP2017527561A5 publication Critical patent/JP2017527561A5/ja
Priority to JP2020072573A priority Critical patent/JP6983273B2/ja
Application granted granted Critical
Publication of JP6692350B2 publication Critical patent/JP6692350B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017512320A 2014-09-05 2015-09-03 リジン特異的なデメチラーゼ−1の阻害剤 Expired - Fee Related JP6692350B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020072573A JP6983273B2 (ja) 2014-09-05 2020-04-14 リジン特異的なデメチラーゼ−1の阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046842P 2014-09-05 2014-09-05
US62/046,842 2014-09-05
PCT/US2015/048429 WO2016037005A1 (en) 2014-09-05 2015-09-03 Inhibitors of lysine specific demethylase-1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020072573A Division JP6983273B2 (ja) 2014-09-05 2020-04-14 リジン特異的なデメチラーゼ−1の阻害剤

Publications (3)

Publication Number Publication Date
JP2017527561A JP2017527561A (ja) 2017-09-21
JP2017527561A5 true JP2017527561A5 (esLanguage) 2018-10-18
JP6692350B2 JP6692350B2 (ja) 2020-05-13

Family

ID=55440376

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017512320A Expired - Fee Related JP6692350B2 (ja) 2014-09-05 2015-09-03 リジン特異的なデメチラーゼ−1の阻害剤
JP2020072573A Expired - Fee Related JP6983273B2 (ja) 2014-09-05 2020-04-14 リジン特異的なデメチラーゼ−1の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020072573A Expired - Fee Related JP6983273B2 (ja) 2014-09-05 2020-04-14 リジン特異的なデメチラーゼ−1の阻害剤

Country Status (17)

Country Link
US (3) US9822119B2 (esLanguage)
EP (1) EP3189038B1 (esLanguage)
JP (2) JP6692350B2 (esLanguage)
KR (1) KR102476459B1 (esLanguage)
CN (2) CN112125901A (esLanguage)
AU (2) AU2015311805B2 (esLanguage)
BR (1) BR112017004334A2 (esLanguage)
CA (1) CA2960188A1 (esLanguage)
CL (1) CL2017000521A1 (esLanguage)
CO (1) CO2017002191A2 (esLanguage)
EA (1) EA201790376A1 (esLanguage)
EC (1) ECSP17013466A (esLanguage)
ES (1) ES2935114T3 (esLanguage)
IL (1) IL250876B (esLanguage)
MX (1) MX381597B (esLanguage)
SG (2) SG10202008486SA (esLanguage)
WO (1) WO2016037005A1 (esLanguage)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112125901A (zh) * 2014-09-05 2020-12-25 赛尔基因昆蒂赛尔研究公司 赖氨酸特异性脱甲基酶-1的抑制剂
CN107849611A (zh) 2015-06-12 2018-03-27 奥瑞泽恩基因组学股份有限公司 与lsd1抑制剂相关的生物标志物及其用途
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017079476A1 (en) 2015-11-05 2017-05-11 Mirati Therapeutics, Inc. Lsd1 inhibitors
PL3381896T3 (pl) 2015-11-27 2023-05-08 Taiho Pharmaceutical Co., Ltd. Związek bifenylowy lub jego sól
US9809541B2 (en) 2015-12-29 2017-11-07 Mirati Therapeutics, Inc. LSD1 inhibitors
CN109195593A (zh) 2016-03-15 2019-01-11 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
US11034991B2 (en) 2016-03-16 2021-06-15 Oryzon Genomics S.A. Methods to determine KDM1A target engagement and chemoprobes useful therefor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN105924397B (zh) * 2016-04-29 2017-11-24 河南省农业科学院植物保护研究所 一种1,5‑二芳基‑3‑甲酸酯吡唑类化合物、制备方法及用途
KR20210019607A (ko) * 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
IL311645B2 (en) * 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
EP3535420A1 (en) 2016-11-03 2019-09-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
MX391414B (es) * 2017-05-26 2025-03-21 Taiho Pharmaceutical Co Ltd Compuesto novedoso de bifenilo o sal del mismo.
JP6738962B2 (ja) * 2017-05-26 2020-08-12 大鵬薬品工業株式会社 新規なビフェニル化合物を用いた抗腫瘍効果増強剤
US12435128B2 (en) 2017-05-31 2025-10-07 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
BR112020000827A2 (pt) 2017-08-03 2020-07-21 Oryzon Genomics, S.A. métodos de tratamento de alterações de comportamento
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
ES3053813T3 (en) 2019-03-20 2026-01-26 Oryzon Genomics Sa Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
SG11202109159VA (en) 2019-03-20 2021-10-28 Oryzon Genomics Sa Methods of treating borderline personality disorder
AU2020297596A1 (en) 2019-06-20 2022-02-03 Celgene Corporation Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
EP3994280A1 (en) 2019-07-05 2022-05-11 Oryzon Genomics, S.A. Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
ES3034158T3 (en) 2019-11-13 2025-08-13 Taiho Pharmaceutical Co Ltd Novel salt of terphenyl compound
EP4306520A4 (en) * 2021-03-11 2025-05-07 Medshine Discovery Inc. THIOPHENE COMPOUND AND ITS USE
WO2022199662A1 (zh) * 2021-03-24 2022-09-29 四川汇宇制药股份有限公司 一种多环化合物及其应用
EP4319732A1 (en) 2021-04-08 2024-02-14 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
US20250032454A1 (en) * 2021-10-18 2025-01-30 Imago Biosciences, Inc. Kdm1a inhibitors for the treatment of disease
CN118146165A (zh) * 2021-11-29 2024-06-07 郑州大学 一种2,3,5-三取代吡嗪类化合物及其制备方法和应用
EP4467537A4 (en) * 2022-01-25 2025-04-30 Chengdu Easton Biopharmaceuticals Co., Ltd. PYRIDINE DERIVATIVE, MANUFACTURING METHOD THEREOF AND USE THEREOF
CN116836167B (zh) * 2022-03-25 2025-09-09 腾讯科技(深圳)有限公司 咪唑并[1,2-a]吡嗪或吡唑并[1,5-a]嘧啶衍生物及其用途
CN119546292A (zh) 2022-05-09 2025-02-28 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗恶性周围神经鞘瘤(mpnst)的方法
JP2025516648A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Lsd1阻害薬を用いるnf1変異腫瘍の治療法
EP4622635A1 (en) 2022-11-24 2025-10-01 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
WO2024208187A1 (zh) * 2023-04-03 2024-10-10 上海复星医药(集团)股份有限公司 氮杂芳基化合物及其作为lsd1抑制剂的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432975B1 (en) * 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
WO2002102313A2 (en) * 2001-06-19 2002-12-27 Bristol-Myers Squibb Company Pyrimidine inhibitors of phosphodiesterase (pde) 7
US7423148B2 (en) 2002-11-21 2008-09-09 Chiron Corporation Small molecule PI 3-kinase inhibitors and methods of their use
JP2006509763A (ja) * 2002-11-22 2006-03-23 メルク エンド カムパニー インコーポレーテッド Nr2b受容体アンタゴニストとしての2−[(4−ベンジル)−1−ピペリジニル)メチル]ベンゾイミダゾール−5−オール誘導体
WO2005058876A1 (en) * 2003-12-16 2005-06-30 Gpc Biotech Ag Pyrazine derivatives as effective compounds against infectious diseases
JP2007532676A (ja) * 2004-04-13 2007-11-15 イカジェン インコーポレイテッド カリウムイオンチャネル調節剤としての多環式ピリジン
AU2006236387A1 (en) * 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl CB1 antagonists
FR2896800B1 (fr) * 2006-01-30 2008-04-11 Servier Lab Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
PL2323992T3 (pl) * 2008-07-29 2017-01-31 Boehringer Ingelheim International Gmbh 5-alkinylo-pirymidyny
EP2258865A1 (en) 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer
RU2012132682A (ru) 2009-12-31 2014-02-10 Пирамал Энтерпрайзис Лимитед Ингибиторы диацилглицерин ацилтрансферазы
ES2564352T3 (es) 2010-04-20 2016-03-22 Università Degli Studi Di Roma "La Sapienza" Derivados de tranilcipromina como inhibidores de la histona-desmetilasa LSD1 y/o LSD2
US9006449B2 (en) * 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
KR101351919B1 (ko) 2012-05-23 2014-01-24 현대모비스 주식회사 차선 유지 보조 시스템 및 방법
EP2925307B1 (en) 2012-11-30 2020-10-28 McCord, Darlene E. Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition
AR098203A1 (es) 2013-11-13 2016-05-18 Dow Global Technologies Llc Reactivo de ensayo de formaldehído
SI3080100T1 (sl) * 2013-12-11 2023-04-28 Celgene Quanticel Research, Inc. Inhibitorji lizin specifične demetilaze-1
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
CN112125901A (zh) * 2014-09-05 2020-12-25 赛尔基因昆蒂赛尔研究公司 赖氨酸特异性脱甲基酶-1的抑制剂

Similar Documents

Publication Publication Date Title
JP2017527561A5 (esLanguage)
JP2017502940A5 (esLanguage)
JP2017519781A5 (esLanguage)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2017514830A5 (esLanguage)
JP2017521407A5 (esLanguage)
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
EA201590345A1 (ru) Способы лечения рака с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона
JP2017523152A5 (esLanguage)
JP2017513894A5 (esLanguage)
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
JP2016531126A5 (esLanguage)
BR112015021027A8 (pt) compostos terapêuticos, seus usos, e composições farmacêuticas
JP2016522172A5 (esLanguage)
JP2014511892A5 (esLanguage)
RU2017101829A (ru) Пиразоловые соединения в качестве модуляторов fshr и пути их применения
JP2016515560A5 (esLanguage)
EA201691629A1 (ru) Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
RU2017145930A (ru) МОДУЛЯТОРЫ ROR ГАММА (RORγ)
JP2019510810A5 (esLanguage)
JP2016514159A5 (esLanguage)
JP2016540742A5 (esLanguage)
JP2016040288A5 (esLanguage)
MX387207B (es) Inhibidores de proteína quinasa, método de preparación y su uso médico.
JP2016528273A5 (esLanguage)